

首页 期刊概况 编委会 期刊内容 特邀审稿 投稿指南 出版发行

203~206.新型免疫调节剂泊马度胺抗肿瘤治疗临床转化的现状[J]. 邹彬镔, 石庆之. 中国肿瘤生物治疗杂志, 2014, 21(2)

新型免疫调节剂泊马度胺抗肿瘤治疗临床转化的现状 点此下载全文

## 邹彬镇 石庆之

南昌大学 第二附属医院 血液科, 江西 南昌 330006; 南昌大学研究生院 医学部, 江西 南昌 330006; 南昌大学 第二附属医院 血液科, 江西 南昌 330006 基金项目。

DOI: 10.3872/j.issn.1007-385X.2014.2.015

摘要:

泊马度胺(pomalidomide)为高效的第三代免疫调节剂(immunomodulatory drug,IMiD),其药理机制类似第一代IMiD沙利度胺,但较后者具有更强的体内外抗血管新生、抗肿瘤、抗炎症及抗骨髓瘤作用,且不良反应相对较少,患者口服耐受性良好。2013年2月,泊马度胺已获美国FDA批准用于复发/难治多发性骨髓瘤(multiple myeloma,MM)患者。本文重点就泊马度胺治疗复发/难治MM、骨髓纤维化、免疫球蛋白轻链型淀粉样变性(immunoglobulin light-chain amyloi dosis,AL)、小细胞肺癌及其他晚期实体肿瘤的临床转化现状作一讨论。

关键词: 泊马度胺 免疫调节剂 多发性骨髓瘤 抗肿瘤 临床转化

Current status of bench-to-bedside translation of the new immunomodulatory drug pomalidomide in treating malignancies <u>Download Fulltext</u>

## Zou Binbin Shi Qingzhi

Department of Hematology, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China; Department of Medicine, Graduate School of Nanchang University, Nanchang 330006, Jiangxi, China; Department of Hematology, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China

Fund Project:

## Abstract:

Pomalidomide is a highly potent third-generation immunomodulatory drug (IMiD), with pharmacologic properties similar to those of the first-generation drug thalidomide. However, compared with thalidomide, pomalidomide has stronger antiangiogenic, antineoplastic, and anti-inflammatory, and anti-myeloma activities in vitro and in vivo, with less side effects and better oral tolerance. In February, 2013, pomalidomide has been approved by the U.S. Food and Drug Administration for use in the treatment of relapsed and refractory multiple myeloma (MM). This review will focus on the recent advances on the translation of pomalidomide from bench to bedside as a therapeutic agent for relapsed and refractory multiple myeloma, myelofibrosis, immunoglobulin light-chain amyloidosis (AL), small cell lung cancer (SCLC), and other advanced solid tumors.

Keywords:pomalidomide immunomodulatory drug(IMiD) multiple myeloma(MM) antitumor clinical transformation

查看全文 查看/发表评论 下载PDF阅读器

Copyright © Biother.Org™ All Rights Reserved; ISSN: 1007-385X CN 31-1725 主管单位:中国科学技术协会 主办单位:中国免疫学会、中国抗癌学会地址:上海市杨浦区翔殷路800号 邮政编码: 200433 京ICP备06011393号-2 本系统由北京勤云科技发展有限公司设计